Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Article in Russian | MEDLINE | ID: mdl-32929938

ABSTRACT

This review aims at describing clinical benefits and characteristics of the main highly effective disease modifying drugs (DMD) for multiple sclerosis (MS): alemtuzumab, cladribine tablets, ocrelizumab, natalizumab, fingolimod based on the efficacy and safety. The authors highlight that all MS DMDs have certain benefits and features that shall be considered in prescribing pharmacotherapy. Cladribine in tablets are comparable by the efficacy to other modern highly effective second-line drugs, have a high level of evidence and a favorable safety profile, as well as the most preferred benefit/risk ratio among other MS DMDs indicated for the treatment of highly active MS, which offers an advantage to the drug. The use of cladribine in tablets will contribute to further study of the efficacy and safety of this highly efficient drug for MS treatment.


Subject(s)
Multiple Sclerosis, Relapsing-Remitting , Multiple Sclerosis , Cladribine , Fingolimod Hydrochloride , Humans , Immunosuppressive Agents
2.
Eksp Klin Gastroenterol ; (6): 80-8, 2016.
Article in Russian | MEDLINE | ID: mdl-30280811

ABSTRACT

Nonsteroidal anti-inflammatory drugs (NSAIDs) are among the most demanded drugs. Paper presents the data review on the drug activity mechanisms, effectiveness, safety, and major drug interactions of NSAIDs at co-morbid conditions in different age groups, as well as measures of prevention of NSAID-gastropathy, which can occur even against the use of small doses of NSAIDs. The existing recommendations on the selection of NSAIDs and the complex therapy with drugs of this pharmacological group are shown in considering the individual characteristics of the patient, the pharmacological properties of drugs, the clinical picture of the disease, the presence of risk factors for adverse reactions and drug interactions.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Stomach Diseases/chemically induced , Stomach Diseases/metabolism , Adolescent , Adult , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Child , Child, Preschool , Comorbidity , Drug Interactions , Female , Humans , Male , Risk Factors , Stomach Diseases/epidemiology , Stomach Diseases/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...